Elevating delivery of provider-administered cardiology medications: Insights & recommendations from the 2025 Becker’s-Alnylam survey
Health systems are entering a new era of cardiology care: one where pharmacy, finance and cardiovascular leaders must work together to improve access to provider-administered medications.
But scaling delivery for emerging therapies — such as those for rare cardiac conditions like ATTR amyloidosis — brings new operational challenges. From patient identification to access pathways, today's leaders need systemwide strategies that reduce friction without compromising care.
This new report shares findings from a Becker's Healthcare survey conducted in partnership with Alnylam Pharmaceuticals, featuring insights from 100+ health system leaders. It highlights how organizations like Advocate Health, Baptist Health South Florida and Fairview Pharmacy Services are addressing delivery challenges through systemwide collaboration and pharmacy-led strategies.
Download to learn:
But scaling delivery for emerging therapies — such as those for rare cardiac conditions like ATTR amyloidosis — brings new operational challenges. From patient identification to access pathways, today's leaders need systemwide strategies that reduce friction without compromising care.
This new report shares findings from a Becker's Healthcare survey conducted in partnership with Alnylam Pharmaceuticals, featuring insights from 100+ health system leaders. It highlights how organizations like Advocate Health, Baptist Health South Florida and Fairview Pharmacy Services are addressing delivery challenges through systemwide collaboration and pharmacy-led strategies.
Download to learn:
- Why patient identification workflows remain fragmented — and proven ways to address it
- How centralized pharmacy services reduce burden while improving treatment access
- What finance, pharmacy and cardiology teams are doing together to optimize buy-and-bill programs
Please fill out the form to download the whitepaper.